ATE326264T1 - Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung - Google Patents

Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung

Info

Publication number
ATE326264T1
ATE326264T1 AT02738838T AT02738838T ATE326264T1 AT E326264 T1 ATE326264 T1 AT E326264T1 AT 02738838 T AT02738838 T AT 02738838T AT 02738838 T AT02738838 T AT 02738838T AT E326264 T1 ATE326264 T1 AT E326264T1
Authority
AT
Austria
Prior art keywords
production
lactic acid
active ingredients
controlled release
pharmaceutical formulations
Prior art date
Application number
AT02738838T
Other languages
English (en)
Inventor
Kazumichi Yamamoto
Nakagyo-Ku Agaru
Akiko Yamada
Yoshio Hata
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26617910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE326264(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE326264T1 publication Critical patent/ATE326264T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT02738838T 2001-06-29 2002-06-28 Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung ATE326264T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001199484 2001-06-29
JP2001340993 2001-11-06

Publications (1)

Publication Number Publication Date
ATE326264T1 true ATE326264T1 (de) 2006-06-15

Family

ID=26617910

Family Applications (3)

Application Number Title Priority Date Filing Date
AT08003261T ATE509668T1 (de) 2001-06-29 2002-06-28 Zusammensetzung mit kontrollierter freisetzung und herstellungsverfahren dafür
AT02738838T ATE326264T1 (de) 2001-06-29 2002-06-28 Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
AT04076939T ATE387937T1 (de) 2001-06-29 2002-06-28 Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer und hydroxynaphthalin-carbonsäure, sowie deren herstellung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08003261T ATE509668T1 (de) 2001-06-29 2002-06-28 Zusammensetzung mit kontrollierter freisetzung und herstellungsverfahren dafür

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04076939T ATE387937T1 (de) 2001-06-29 2002-06-28 Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer und hydroxynaphthalin-carbonsäure, sowie deren herstellung

Country Status (33)

Country Link
US (4) US7429559B2 (de)
EP (3) EP1949936B1 (de)
JP (5) JP2003206240A (de)
KR (2) KR100961413B1 (de)
CN (3) CN100577206C (de)
AR (2) AR034641A1 (de)
AT (3) ATE509668T1 (de)
AU (2) AU2002311631B2 (de)
BR (1) BRPI0210561B8 (de)
CA (1) CA2455392C (de)
CO (1) CO5540367A2 (de)
CR (1) CR11283A (de)
CY (2) CY1105071T1 (de)
CZ (1) CZ306327B6 (de)
DE (2) DE60225481T2 (de)
DK (2) DK1949936T3 (de)
ES (2) ES2263788T5 (de)
HU (1) HU230351B1 (de)
IL (3) IL159059A0 (de)
MX (1) MXPA03011456A (de)
MY (1) MY142066A (de)
NO (1) NO331883B1 (de)
NZ (2) NZ541884A (de)
PE (1) PE20030066A1 (de)
PL (1) PL204903B1 (de)
PT (2) PT1330293E (de)
RU (1) RU2301661C2 (de)
SG (1) SG180015A1 (de)
SI (1) SI1949936T1 (de)
SK (1) SK287577B6 (de)
TW (2) TW200526267A (de)
WO (1) WO2003002092A2 (de)
ZA (1) ZA200309152B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ505651A (en) 1998-01-16 2003-08-29 Takeda Chemical Industries Ltd Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer
TW200526267A (en) * 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
CA2490351C (en) * 2002-06-25 2011-11-01 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
CA2516107C (en) 2003-04-10 2013-12-24 Ehud Zeigerson A method for production of emulsion-based microparticles
WO2005009356A2 (en) * 2003-07-15 2005-02-03 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
WO2005009357A2 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US20070149457A1 (en) * 2005-12-13 2007-06-28 Byron Rubin Stable solid forms of enterostatin
CN101400363B (zh) 2006-01-18 2012-08-29 昌达生物科技公司 具有增强的稳定性的药物组合物
US7858663B1 (en) * 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
EA016176B1 (ru) 2006-12-18 2012-02-28 Такеда Фармасьютикал Компани Лимитед Композиция с замедленным высвобождением и способ её получения
US20110319987A1 (en) * 2009-05-20 2011-12-29 Arsenal Medical Medical implant
KR101811797B1 (ko) * 2013-04-03 2017-12-22 동국제약 주식회사 도네페질을 포함하는 비경구투여용 약제학적 조성물
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
CN103751851A (zh) * 2014-01-17 2014-04-30 东华大学 一种无机/有机多药物控释复合纳米纤维支架的制备方法
KR101558083B1 (ko) * 2014-04-07 2015-10-07 에스케이케미칼주식회사 약물함유 고분자미립구 제조방법
EA201692083A1 (ru) 2014-04-16 2017-03-31 Вейкс-Фарма Гмбх Фармацевтическая композиция для ветеринарии и ее применение
US10787920B2 (en) 2016-10-12 2020-09-29 General Electric Company Turbine engine inducer assembly
KR102089737B1 (ko) 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
EP4611745A1 (de) 2022-10-31 2025-09-10 Takeda Pharmaceutical Company Limited Dosierung von orexin-typ-2-rezeptoragonisten
WO2025229492A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Orexin type 2 receptor agonist microcapsules for sustained release dosing
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297033A (en) * 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3565869A (en) * 1968-12-23 1971-02-23 American Cyanamid Co Extrudable and stretchable polyglycolic acid and process for preparing same
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US3912692A (en) * 1973-05-03 1975-10-14 American Cyanamid Co Process for polymerizing a substantially pure glycolide composition
US3890283A (en) * 1973-06-04 1975-06-17 American Cyanamid Co Process for post-polymerizing polyglycolic acid
US4258063A (en) 1978-06-23 1981-03-24 Henkel Corporation Self-emulsifying cosmetic base
US4249531A (en) * 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4605730A (en) * 1982-10-01 1986-08-12 Ethicon, Inc. Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
US4539981A (en) * 1982-11-08 1985-09-10 Johnson & Johnson Products, Inc. Absorbable bone fixation device
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
CH656884A5 (de) † 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CA1256638A (en) * 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
DE3678308D1 (de) 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
ATE168391T1 (de) * 1990-04-13 1998-08-15 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare polymere, ihre herstellung und ihre verwendung
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
US5353086A (en) * 1993-05-03 1994-10-04 Eastman Kodak Company Textured surface with canted channels for an automatic tray processor
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
US5594091A (en) * 1994-02-21 1997-01-14 Takeda Chemical Industries, Ltd. Matrix for sustained-release preparation
JP3490171B2 (ja) 1994-02-21 2004-01-26 武田薬品工業株式会社 生体内分解性ポリマーの末端カルボキシル基におけるエステル
US5763513A (en) * 1994-05-19 1998-06-09 Mitsui Toatsu Chemicals, Inc. L-lactic acid polymer composition, molded product and film
JPH08259460A (ja) * 1995-01-23 1996-10-08 Takeda Chem Ind Ltd 徐放性製剤の製造法
JP3902272B2 (ja) * 1995-09-04 2007-04-04 武田薬品工業株式会社 徐放性製剤の製造法
US5922662A (en) * 1996-08-07 1999-07-13 Colgate Palmolive Company High foaming nonionic surfactant based liquid detergent
CA2219698C (en) 1996-10-31 2007-09-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
JPH10273447A (ja) * 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
WO1998032423A1 (en) 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Sustained-release microspheres, their production and use
JPH11269094A (ja) 1998-01-16 1999-10-05 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
NZ505651A (en) * 1998-01-16 2003-08-29 Takeda Chemical Industries Ltd Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer
US6114495A (en) * 1998-04-01 2000-09-05 Cargill Incorporated Lactic acid residue containing polymer composition and product having improved stability, and method for preparation and use thereof
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
CA2355186C (en) * 1998-12-15 2008-03-18 Takeda Chemical Industries, Ltd. Process for producing polymer
JP2000238051A (ja) † 1999-02-23 2000-09-05 Kansei Corp 表皮シートの発泡成形型へのセッティング方法
JP2001081043A (ja) * 1999-07-15 2001-03-27 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
CN1361685A (zh) * 1999-07-15 2002-07-31 武田药品工业株式会社 缓释组合物、其制备方法和用途
JP3837607B2 (ja) † 2000-05-29 2006-10-25 Ｔｃｍ株式会社 マスト用溶接位置決め治具
CN1269870C (zh) 2000-08-07 2006-08-16 和光纯药工业株式会社 乳酸聚合物及其制备方法
AU2002218494A1 (en) * 2000-11-29 2002-06-11 Takeda Chemical Industries Ltd. Medicinal compositions and process for producing the same
WO2002047722A1 (en) * 2000-12-15 2002-06-20 Takeda Chemical Industries, Ltd. Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof
TW200526267A (en) * 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same

Also Published As

Publication number Publication date
DK1330293T3 (da) 2006-09-11
EP1949936B1 (de) 2011-05-18
PL367518A1 (pl) 2005-02-21
CN100348265C (zh) 2007-11-14
SK15602003A3 (sk) 2004-06-08
KR100961413B1 (ko) 2010-06-09
JP4819172B2 (ja) 2011-11-24
CN1868458A (zh) 2006-11-29
DE60211464T2 (de) 2006-09-07
JP2004238400A (ja) 2004-08-26
ZA200309152B (en) 2005-01-26
RU2301661C2 (ru) 2007-06-27
PL204903B1 (pl) 2010-02-26
DK1949936T3 (da) 2011-08-15
CZ306327B6 (cs) 2016-12-07
PT1330293E (pt) 2006-08-31
NZ529969A (en) 2005-10-28
EP1491236B1 (de) 2008-03-05
JP2003206240A (ja) 2003-07-22
ES2263788T3 (es) 2006-12-16
WO2003002092A2 (en) 2003-01-09
TW200526267A (en) 2005-08-16
EP1491236A1 (de) 2004-12-29
DE60211464T3 (de) 2011-03-17
BRPI0210561B8 (pt) 2021-05-25
CY1111708T1 (el) 2015-10-07
US20030134800A1 (en) 2003-07-17
US20120283187A1 (en) 2012-11-08
CN1724066A (zh) 2006-01-25
CA2455392C (en) 2011-11-22
EP1949936A3 (de) 2008-10-08
DE60225481T2 (de) 2009-02-26
CY1105071T1 (el) 2010-03-03
EP1330293B1 (de) 2006-05-17
CN1535168A (zh) 2004-10-06
SK287577B6 (sk) 2011-03-04
SI1949936T1 (sl) 2011-08-31
BRPI0210561B1 (pt) 2018-08-14
KR100916173B1 (ko) 2009-09-08
EP1330293A2 (de) 2003-07-30
NO20035738D0 (no) 2003-12-19
ES2366677T3 (es) 2011-10-24
CR11283A (es) 2010-05-31
IL159059A (en) 2011-06-30
PE20030066A1 (es) 2003-03-20
KR20090020708A (ko) 2009-02-26
MY142066A (en) 2010-08-30
CA2455392A1 (en) 2003-01-09
PT1949936E (pt) 2011-07-12
ATE509668T1 (de) 2011-06-15
IL159059A0 (en) 2004-05-12
EP1330293B2 (de) 2010-10-27
HK1056332A1 (en) 2004-02-13
DE60225481D1 (de) 2008-04-17
MXPA03011456A (es) 2004-07-01
US8246987B2 (en) 2012-08-21
WO2003002092A3 (en) 2003-04-10
AU2002311631B2 (en) 2007-02-08
CN1292796C (zh) 2007-01-03
US8067030B2 (en) 2011-11-29
CO5540367A2 (es) 2005-07-29
CZ20033493A3 (cs) 2004-08-18
JP4819173B2 (ja) 2011-11-24
US8815801B2 (en) 2014-08-26
KR20040018402A (ko) 2004-03-03
US20110166084A1 (en) 2011-07-07
AU2006246508A1 (en) 2006-12-21
SG180015A1 (en) 2012-05-30
DE60211464D1 (de) 2006-06-22
IL186782A0 (en) 2008-02-09
HUP0400378A2 (hu) 2004-12-28
HU230351B1 (hu) 2016-02-29
JP2009167203A (ja) 2009-07-30
JP2010189428A (ja) 2010-09-02
AR034641A1 (es) 2004-03-03
ATE387937T1 (de) 2008-03-15
US7429559B2 (en) 2008-09-30
AR098261A2 (es) 2016-05-18
NO331883B1 (no) 2012-04-23
NZ541884A (en) 2007-01-26
RU2004102507A (ru) 2005-03-10
JP2010189427A (ja) 2010-09-02
ES2263788T5 (es) 2011-02-22
CN100577206C (zh) 2010-01-06
EP1949936A2 (de) 2008-07-30
DK1330293T4 (da) 2011-01-10
AU2006246508B2 (en) 2008-09-04
BR0210561A (pt) 2004-06-22
US20090005318A1 (en) 2009-01-01
TWI332407B (en) 2010-11-01
HUP0400378A3 (en) 2010-01-28
NO20035738L (no) 2004-02-27

Similar Documents

Publication Publication Date Title
ATE326264T1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
ATE397440T1 (de) Pharmazeutische zubereitungen von antineoplastischen wirkstoffen, insbesondere temozolomid, verfahren zu ihrer herstellung und deren verwendung
DE60001546D1 (de) Liponsaürederivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE60232147D1 (de) Pharmazeutische zubereitung mit verzögerter wirkstoff-freisetzung enthaltend milchsäure-glycolsäure copolymer, und verfahren zu deren herstellung
ATE396198T1 (de) 17alpha-alkyl-17beta-oxy-estratriene und zwischenprodukte zu deren herstellung, verwendung der 17alpha-alkyl-17beta-oxy-estratriene zur herstellung von arzneimitteln sowie pharmazeutische präparate
EP2322146A3 (de) Mikrokapselformulierung mit zwei pharmazeutischen Wirkstoffen
ATE355829T1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
ATE334663T1 (de) Arzneimittelzusammensetzung mit verzögerter wirkstoffabgabe
EP1483277A4 (de) Konjugate biologisch aktiver verbindungen, verfahren zu deren herstellung und anwendung, formulierung und pharmazeutische anwendungen davon
EE05311B1 (et) Meetod mineraalse t„iteaine t””tlemiseks poldialklsiloksaani ja rasvhappega, saades hdrofoobsed t„iteained, ja nende kasutamine polmeerides ''hingavate'' kilede jaoks
HRP20040849A2 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
DE69904954D1 (de) Verfahren zur herstellung neuer fenofibrathaltiger arzneiformulierungen, dadurch hergestellte arzneiformulierungen und ihre verwendung
DE60108255D1 (de) Clarithromycin enthaltende zubereitung mit verlängerter freisetzung
DE60313359D1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
ATE529097T1 (de) Pharmazeutische zubereitung in form einer paste mit einem säurelabilen wirkstoff
ATE327737T1 (de) Verfahren zur herstellung von arzneistoffgranulatkörnern, die arzneistoffgranulatkörner sowie diese enthaltende pharmazeutische zubereitungen
ATE367803T1 (de) Subcutane implantate mit begrenzter initialer wirkstoff-freisetzung und deren anschliessende lineare veränderliche verlängerte freisetzung
DE60042972D1 (de) Trimetazidine enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe und Verfahren zur Herstellung
DE60022332D1 (de) Ketoprofen mikrogranulat, verfahren zur herstellung desselben sowie pharmazeutische zusammensetzungen
WO2001013898A3 (en) Pharmaceutical formulations with different release times
ATE305799T1 (de) Stabilisierte pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung, mit einem antibiotikum und einem expektorans
ATE245974T1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
ATE290543T1 (de) Pharmazeutische zusammensetzungen mit oligosacchariden und deren herstellung
ATE279180T1 (de) Feste pharmazeutische zubereitungen mit nanosols aus chitosan, sowie deren herstellung
EA200700877A1 (ru) Диспергируемая во рту фармацевтическая композиция и способ ее получения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1330293

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1330293

Country of ref document: EP